말단비대증 환자에서 소마토스타틴 유사체 사용에 대한 권고안

• Published in: The Korean journal of medicine Vol. 94; no. 6; pp. 485 - 494
• Main Authors: 진상욱, Sang Ouk Chin, 구철룡, Cheol Ryong Ku, 김병준, Byung Joon Kim, 김성운, Sung-woon Kim, 박경혜, Kyeong Hye Park, 송기호, Kee Ho Song, 오승준, Seungjoon Oh, 윤현구, Hyun Koo Yoon, 이은직, Eun Jig Lee, 이정민, Jung Min Lee, 임정수, Jung Soo Lim, 김정희, Jung Hee Kim, 김광준, Kwang Joon Kim, 진흥용, Heung Yong Jin, 김대중, Dae Jung Kim, 이경애, Kyung Ae Lee, 문성수, Seong-su Moon, 임동준, Dong Jun Lim, 신동엽, Dong Yeob Shin, 김세화, Se Hwa Kim, 권민정, Min Jeong Kwon, 김하영, Ha Young Kim, 김진화, Jin Hwa Kim, 김동선, Dong Sun Kim, 김종화, Chong Hwa Kim
• Format: Journal Article
• Language: Korean
• Published: 대한내과학회 01.12.2019
• Subjects: Acromegaly; Lanreotide; Octreotide; Pasireotide; Somatostatin; 내과학; 말단비대증; 소마토스타틴 유사체
• ISSN: 1738-9364; 2289-0769
• DOI: 10.3904/kjm.2019.94.6.485

Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical man-agement is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrep-ancies among expert opinions, the experts voted to determine the recommended approach. (Korean J Med 2019;94:485-494)